Polyarticular juvenile idiopathic arthritis

This study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…

This study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…

This study is for children aged 2 to 17 with polyarticular juvenile idiopathic arthritis (JIA) whose first TNF inhibitor medication did not work well enough. It compares three different non-TNFi drugs (abatacept, tocilizumab, tofacitinib) against a second TNF inhibitor to see whi…

This study tests a daily pill called filgotinib in children aged 8 to 17 with a type of arthritis that affects multiple joints. The goal is to see if the drug is safe and helps control the disease over 18 weeks. About 65 participants will take the drug and be monitored for side e…

This early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…

This early-stage trial tests a new type of CAR-T cell therapy in 11 children with severe rheumatic diseases like juvenile dermatomyositis and arthritis that haven't improved with standard treatments. The therapy uses specially engineered immune cells to target and calm the overac…